331 related articles for article (PubMed ID: 32917636)
21. Disrupting the adult globin promoter alleviates promoter competition and reactivates fetal globin gene expression.
Topfer SK; Feng R; Huang P; Ly LC; Martyn GE; Blobel GA; Weiss MJ; Quinlan KGR; Crossley M
Blood; 2022 Apr; 139(14):2107-2118. PubMed ID: 35090172
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
23. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
[TBL] [Abstract][Full Text] [Related]
24. Transcription factor competition at the γ-globin promoters controls hemoglobin switching.
Liu N; Xu S; Yao Q; Zhu Q; Kai Y; Hsu JY; Sakon P; Pinello L; Yuan GC; Bauer DE; Orkin SH
Nat Genet; 2021 Apr; 53(4):511-520. PubMed ID: 33649594
[TBL] [Abstract][Full Text] [Related]
25. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
26. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of two β globin gene cluster mutations leading to the hereditary persistence of fetal hemoglobin (HPFH) phenotype.
Hariharan P; Sawant M; Gorivale M; Manchanda R; Colah R; Ghosh K; Nadkarni A
Mol Biol Rep; 2017 Oct; 44(5):413-417. PubMed ID: 28879539
[TBL] [Abstract][Full Text] [Related]
28. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
29. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs.
Han W; Qiu HY; Sun S; Fu ZC; Wang GQ; Qian X; Wang L; Zhai X; Wei J; Wang Y; Guo YL; Cao GH; Ji RJ; Zhang YZ; Ma H; Wang H; Zhao M; Wu J; Bi L; Chen QB; Li Z; Yu L; Mou X; Yin H; Yang L; Chen J; Yang B; Zhang Y
Cell Stem Cell; 2023 Dec; 30(12):1624-1639.e8. PubMed ID: 37989316
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic expression of Hb F in common high Hb F determinants in Thailand: roles of α-thalassemia, 5' δ-globin BCL11A binding region and 3' β-globin enhancer.
Prakobkaew N; Fucharoen S; Fuchareon G; Siriratmanawong N
Eur J Haematol; 2014 Jan; 92(1):73-9. PubMed ID: 24112054
[TBL] [Abstract][Full Text] [Related]
31. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
[TBL] [Abstract][Full Text] [Related]
32. Original Research: Generation of non-deletional hereditary persistence of fetal hemoglobin β-globin locus yeast artificial chromosome transgenic mouse models: -175 Black HPFH and -195 Brazilian HPFH.
Braghini CA; Costa FC; Fedosyuk H; Neades RY; Novikova LV; Parker MP; Winefield RD; Peterson KR
Exp Biol Med (Maywood); 2016 Apr; 241(7):697-705. PubMed ID: 26946532
[TBL] [Abstract][Full Text] [Related]
33. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
34. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
[TBL] [Abstract][Full Text] [Related]
35. Activation of γ-globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin.
Doerfler PA; Feng R; Li Y; Palmer LE; Porter SN; Bell HW; Crossley M; Pruett-Miller SM; Cheng Y; Weiss MJ
Nat Genet; 2021 Aug; 53(8):1177-1186. PubMed ID: 34341563
[TBL] [Abstract][Full Text] [Related]
36. Potent and uniform fetal hemoglobin induction via base editing.
Mayuranathan T; Newby GA; Feng R; Yao Y; Mayberry KD; Lazzarotto CR; Li Y; Levine RM; Nimmagadda N; Dempsey E; Kang G; Porter SN; Doerfler PA; Zhang J; Jang Y; Chen J; Bell HW; Crossley M; Bhoopalan SV; Sharma A; Tisdale JF; Pruett-Miller SM; Cheng Y; Tsai SQ; Liu DR; Weiss MJ; Yen JS
Nat Genet; 2023 Jul; 55(7):1210-1220. PubMed ID: 37400614
[TBL] [Abstract][Full Text] [Related]
37. Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations.
Woodard KJ; Doerfler PA; Mayberry KD; Sharma A; Levine R; Yen J; Valentine V; Palmer LE; Valentine M; Weiss MJ
Dis Model Mech; 2022 Jun; 15(6):. PubMed ID: 35793591
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
[TBL] [Abstract][Full Text] [Related]
40. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.
Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM
Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
